CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
NCT04718883
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
59
Enrollment
INDUSTRY
Sponsor class
Conditions
Mantle Cell Lymphoma
Interventions
BIOLOGICAL:
CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
Sponsor
Shanghai Ming Ju Biotechnology Co., Ltd.